Phytecs

At a recent Canadian Bar Association seminar, attorney Sara Zborovski (with Norton Rose Fulbright) urged the branding and marketing communities to collectively try to get rid of the stigma and increase the credibility of this [cannabis] industry by not using silly words. She correctly noted that we don’t reference alcohol like ‘booze’ or ‘moonshine’ anymore, and expressed her hope that when we are talking publicly and about the industry. . . [that] we as an industry and... as branding professionals will use [words such as] ‘cannabis’ and ‘marijuana’ and not words such as ‘pot, dope, MJ, weed’. She said, let’s try to increase the level of discussion such that we can increase the credibility of the industry, and added that she thinks this will go a really long way towards protecting our kids. She is 100% correct and we encourage the branding community to apply her advice and suggestions. We do believe this should extend to other words such as indica, sativa and hybrid, since such terms have no actionable meaning to customers or relationship to outcomes and should not impact a purchase decision. Additionally, we hope that the branding and marketing communities encourage efforts to characterize cannabis products by their objective chemistries, which directly translate into effects. By focusing on properly characterized chemistries, the industry can explore the use of structure/function claims to educate consumers and distinguish products.

In his presentation at CannX, Gary explored why positive anecdotal reports from patients on cannabis efficacy does not always align with negative published studies and explained how laboratory data could be used to inform and guide cannabis breeding work to increase efficacy.

Phytecs President Gary Hiller is joining leaders in the medical cannabis field at CannX. Look for his presentation about the importance of developing and using cannabis plants that are targeted for indications in order to be therapeutically effective rather than using generic cannabis.

Phytecs President, Gary Hiller, will be attending and presenting at the #CannX2018 conference next week. For those attending, looking forward to seeing you there! https://cannx.org/2018/agenda-(2)/networking-opportunities

In just a couple of hours Snowden Bishop will be joining leading researchers in the ECS field to talk about the latest research. Participation is free. Tune in at https://bit.ly/2xOPfHR

The DEA’s rescheduling of Epidiolex, a natural botanical medication derived from cannabis, is an historic development that we hope brings relief to patients suffering from intractable diseases. The FDA’s and DEA’s approach to Epidiolex encourages our view that the endocannabinoid system (ECS) is a critically-important drug target and that research and development into innovative means to modulate ECS function must continue.

With Corona investing over $4 billion in the cannabis industry and Coca-Cola reportedly eyeing the market as well, exploring cannabis research and better understanding the ECS is critical in advancing its therapeutic use. We’re bringing together experts to talk future innovation: https://bit.ly/2R14Yfx

Join the discussion! We are hosting a webinar, moderated by The Cannabis Reporter’s host Snowden Bishop to discuss emerging cannabis research and innovations. Participation is free and questions encouraged! Sign up at: https://bit.ly/2R14Yfx

We're excited to announce our FREE webinar discussing the future of #ECS and #cannabis research! It will be led by Snowden Bishop, host of The Cannabis Reporter, featuring top cannabinoid researchers from around the world. Check out our event for details: https://bit.ly/2R14Yfx

Check out this piece from The Fresh Toast on the functionality of #CBD in topical products, featuring research by our own Tamás Bíró. https://thefreshtoast.com//the-purpose-and-functionality-/

The research on nabilone's efficacy in treating the agitation of Alzheimer’s patients is noteworthy when compared to new data by the FDA on the frequency of irritability/agitation as adverse events associated with CBD treatment. That new data shows a reported 3.5x increase of irritability (from 2% to 9%) over placebo at a 10mg dose, which is significant and relevant to the conversation on single compound vs. whole-plant medicine. https://www.fda.gov//PeripheralandCentralNer/UCM605969.pdf

Encouraging news on the efficacy of nabilone--a synthetic analogue of THC--to treat agitation in Alzheimer’s patients. Further research into the activation of cannabinoid receptors could aid millions with significant unmet medical needs. Still, the challenging regulatory issues associated with disparate scheduling of similar CB1 agonists cannot be ignored, with THC in Schedule I, nabilone in Schedule II, and dronabinol in Schedule III. #AAIC18 https://www.nbcnews.com//cannabis-drug-eases-agitation-alz